Debiopharm S.A., Patrys deal

Patrys acquired exclusive, worldwide rights to SC1 ( SC-1) from Debiopharm's Debiovision Inc. unit. Patrys renamed the compound PAT-SC1. The human IgM mAb targeting an isoform of CD55 was originally...